• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

Everolimus(伊维莫司)

[复制链接]
5102 4 成长的烦恼 发表于 2012-1-30 18:39:17 |

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区。

您需要 登录 才可以下载或查看,没有账号?立即注册

x
本帖最后由 虎光着 于 2018-8-24 18:55 编辑

Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).

Background: For patients (pts) with mCRC, treatment options are absent after progression on 5-FU, oxaliplatin, irinotecan, bevacizumab, and cetuximab/panitumumab. Preclinical data demonstrate combined VEGF and mTOR inhibition has greater antiangiogenic and antitumor activity than either monotherapy, and phase I data demonstrated that the combination of B + E is safe and generally well tolerated. This phase II trial evaluates efficacy and tolerability of B+E in mCRC patients who have progressed on standard therapies. Methods: 50 pts with refractory mCRC were treated with B 10 mg/kg q2 wks and E 10 mg PO QD until progression. Blood, skin, and tumor biopsies pre- and on-treatment were collected for markers of response and resistance. Results: 47 of 50 pts had prior B exposure; 42 pts had previously progressed on B. Median number of prior regimens was 4. Although no complete or partial responses were seen, 46% of pts achieved disease control for a median duration of 6.1 months (mos) (range 2.3-12.6): 8 pts had minor responses (median duration of response 4.1 mos, range 2.3-11.9+) and an additional 15 patients had SD (median duration of response 6.7 mos, range 3.2-12.6+). Three patients with prolonged stable disease have been on treatment > 1 year. There was one grade (Gr) 4 adverse event (AE) of hypokalemia. Noteworthy grade 3 AEs related to treatment were hypertension (n = 7), mucositis/proctitis (n = 3), fistula/abcess (n = 3), bowel perforation (n = 1), azotemia/proteinuria (n = 2), fatigue (n = 2), thrombocytopenia (n = 2), hyperglycemia (n = 6), hypokalemia (n = 6), hypophosphatemia (n = 2), hyperlipidemia (n = 3) and hyperbilirubinemia (n = 2). There was one Gr 3 event each of rhabdomyolysis, neuropathy, volume depletion, prolonged QT interval, GI hemorrhage and neutropenia. Other events of interest were: Gr 1-2 mucositis (68%, n = 34), Gr 1-2 hyperlipidemia (64%, n = 32). Biomarker data is pending. Conclusions: B + E has promising activity in refractory mCRC (even in pts who have progressed on a B-based regimen) with a disease control rate of 46%, suggesting B + E may overcome resistance to B.

依维莫司(Everolinus)是诺华公司开发的用来预防移植器官排斥反应的药物,后因其mTOR靶点独特的抗肿瘤活性而越来越受到人们的重视。上述临床是依维莫司联合阿瓦斯汀针对经历过所有标准治疗后的转移性结直肠癌患者的二期临床实验。实验数据结果相当不错,特别是对于之前一直运用阿瓦进行治疗的患者,联合伊维莫司仍然有效,这是极为难得的。这也为经历过所有标准治疗无效后的患者提供了一种可行的治疗方案。期待有更大型的联合实验开展来获取更多的有效数据。
QQ:412286151;QQ群:203323347 肠转患者和家属交流群

4条精彩回复,最后回复于 2018-10-23 12:33

累计签到:19 天
连续签到:1 天
[LV.4]与爱新星
chen20180123  小学五年级 发表于 2018-9-20 15:28:07 | 显示全部楼层 来自: 辽宁大连
不太了解这种药
cdswf  初中一年级 发表于 2018-9-25 12:38:46 来自手机 | 显示全部楼层 来自: 山东
这是个好消息,不知道价格怎么样
卖炭翁  小学四年级 发表于 2018-10-23 12:26:57 来自手机 | 显示全部楼层 来自: 河南郑州
依维莫斯也可以治疗神经内分泌肿瘤。
累计签到:23 天
连续签到:1 天
[LV.4]与爱新星
北极熊欢欢  高中三年级 发表于 2018-10-23 12:33:12 | 显示全部楼层 来自: 江苏南京
这是一个神奇的药

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表